Alnylam Pharma (ALNY) Tops Q4 EPS by 32c

Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.28), $0.32 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $24.02 million versus the consensus estimate of $13.1 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Marlin Business Services (MRLN) Reports Q2 Loss of $1.40
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance